See more : West Vault Mining Inc. (WVM.V) Income Statement Analysis – Financial Results
Complete financial analysis of 23andMe Holding Co. (ME) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 23andMe Holding Co., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Andover Mining Corp. (AOVTF) Income Statement Analysis – Financial Results
- Digital Ally, Inc. (DGLY) Income Statement Analysis – Financial Results
- Spectrum Global Solutions, Inc. (SGSI) Income Statement Analysis – Financial Results
- MetLife, Inc. (MET-PE) Income Statement Analysis – Financial Results
- Phoenix Motor Inc. (PEV) Income Statement Analysis – Financial Results
23andMe Holding Co. (ME)
About 23andMe Holding Co.
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 219.64M | 299.49M | 271.89M | 243.92M | 305.46M | 440.90M |
| Cost of Revenue | 120.26M | 164.99M | 138.95M | 126.91M | 168.03M | 257.91M |
| Gross Profit | 99.38M | 134.50M | 132.95M | 117.01M | 137.43M | 182.99M |
| Gross Profit Ratio | 45.25% | 44.91% | 48.90% | 47.97% | 44.99% | 41.50% |
| Research & Development | 205.36M | 222.60M | 189.38M | 159.86M | 181.28M | 140.53M |
| General & Administrative | 148.33M | 115.98M | 97.38M | 99.15M | 59.39M | 50.29M |
| Selling & Marketing | 85.60M | 119.93M | 100.34M | 43.20M | 110.52M | 190.85M |
| SG&A | 205.74M | 235.91M | 197.72M | 142.35M | 169.91M | 231.24M |
| Other Expenses | 9.63M | -93.00K | -83.00K | 1.32M | 1.34M | 0.00 |
| Operating Expenses | 420.73M | 458.51M | 387.10M | 302.20M | 351.19M | 371.77M |
| Cost & Expenses | 540.99M | 623.50M | 526.05M | 429.12M | 519.22M | 629.68M |
| Interest Income | 14.33M | 9.68M | 277.00K | 1.58M | 6.24M | 5.25M |
| Interest Expense | 0.00 | 0.00 | 277.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 29.48M | 36.50M | 26.15M | 20.25M | 22.25M | 9.90M |
| EBITDA | -291.87M | -291.94M | -228.01M | -164.95M | -191.51M | -173.63M |
| EBITDA Ratio | -132.89% | -96.00% | -95.99% | -67.62% | -47.72% | -40.57% |
| Operating Income | -321.36M | -324.01M | -254.15M | -185.20M | -213.76M | -188.78M |
| Operating Income Ratio | -146.31% | -108.19% | -93.48% | -75.92% | -69.98% | -42.82% |
| Total Other Income/Expenses | -345.28M | 9.58M | 33.18M | 1.58M | -37.11M | 5.25M |
| Income Before Tax | -666.63M | -314.43M | -220.97M | -183.62M | -250.86M | -183.53M |
| Income Before Tax Ratio | -303.51% | -104.99% | -81.27% | -75.28% | -82.13% | -41.63% |
| Income Tax Expense | 73.00K | -2.77M | -3.48M | -255.00K | 38.45M | 9.74M |
| Net Income | -666.70M | -311.66M | -217.49M | -183.36M | -289.31M | -183.53M |
| Net Income Ratio | -303.55% | -104.06% | -79.99% | -75.17% | -94.71% | -41.63% |
| EPS | -1.40 | -13.81 | -9.96 | -9.04 | -12.34 | -9.03 |
| EPS Diluted | -28.01 | -13.81 | -9.96 | -9.04 | -12.34 | -9.03 |
| Weighted Avg Shares Out | 475.98M | 22.58M | 21.83M | 20.32M | 20.32M | 20.32M |
| Weighted Avg Shares Out (Dil) | 23.80M | 22.58M | 21.83M | 20.32M | 20.32M | 20.32M |
23andMe directors resign as the CEO of the genetic-testing company seeks to take it private
ME STOCK NOTICE: An Investigation has been Initiated Against 23andMe Holding Co. for Breaches of Fiduciary Duties – Shareholders are Urged to Contact BFA Law
23andMe faces Nasdaq delisting after its entire board resigns
23andMe faces Nasdaq delisting
Wolf Popper LLP is Investigating Whether the Offer to Acquire 23andMe Holding Co. By Its Controlling Shareholder Is Fair to the Minority Shareholders
How 23andMe Went From Market Darling to Losing Its Entire Board
ME STOCK ALERT: 23andMe Holding Co. Shareholders are Notified that an Investigation has been Initiated Against the Company's Board of Directors and are Urged to Contact BFA Law (NASDAQ:ME)
All 23andMe board members but CEO resign over no adequate buyout offers
23andMe board resigns in feud over CEO Anne Wojcicki's plan to take company private
23andMe's stock tumbles 7% after independent directors quit in clash with CEO over buyout plan
Source: https://incomestatements.info
Category: Stock Reports